Indication for treatment with TCZ
n=93 | |
Joints | 67 (72.0%) |
Skin | 25 (26.9%) |
Lung | 20 (21.5%) |
Myositis | 2 (2.2%) |
Heart | 1 (1.1%) |
Tendinitis | 2 (2.2%) |
Vasculitis | 1 (1.1%) |
Coexisting Castelman-like disease | 1 (1.1%) |
Joints only | 50 (53.8%) |
Joints and skin | 6 (6.5%) |
Joints and lung | 7 (7.5%) |
Joints and myositis | 1 (1.1%) |
Joints, skin and lung | 3 (3.2%) |
Skin only | 8 (8.6%) |
Skin and lung | 4 (4.3%) |
Skin and heart | 1 (1.1%) |
Skin and tendovaginitis | 2 (2.2%) |
Skin, lung and myositis | 1 (2.2%) |
Lung only | 5 (5.4%) |
Vasculitis only | 1 (1.1%) |
Coexisting Castelman-like disease only | 1 (1.1%) |
NA | 3 (3.2%) |
NA, not available; TCZ, tocilizumab.